Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic

Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic

Abstract The 15th Annual Protein Engineering Summit (PEGS) organized by Cambridge Healthtech Institute was held in Boston, USA, from 8 to 12 April 2019. This report highlights the presentations in the Oncology Stream of this meeting with a focus on bispecific antibodies (BsAbs). A variety of BsAb fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antibody therapeutics 2019-10, Vol.2 (4), p.79-87
Hauptverfasser: Li, Hong, Li, You, Wang, Cheng, Wang, Shouye, Ho, Mitchell
Format: Artikel
Sprache:eng
Schlagworte:
Meeting Reports
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 87
container_issue 4
container_start_page 79
container_title Antibody therapeutics
container_volume 2
creator Li, Hong
Li, You
Wang, Cheng
Wang, Shouye
Ho, Mitchell
description Abstract The 15th Annual Protein Engineering Summit (PEGS) organized by Cambridge Healthtech Institute was held in Boston, USA, from 8 to 12 April 2019. This report highlights the presentations in the Oncology Stream of this meeting with a focus on bispecific antibodies (BsAbs). A variety of BsAb formats with different target antigens (CD3, CTLA4, PD-1, PD-L1, EGFR, HER2, BCMA, CD19, CD20, CD38, CD123, TGFβ, PSMA, etc.) have been discussed, in which the T-cell engaging (anti-CD3) BsAb is the most studied construct to exhibit promising immunotherapeutic activities. The BsAb formats include IgG-like structures or antibody fragments composed of antigen-binding sites only. Preclinical and clinical data from different BsAbs demonstrated the potential therapeutic applications in various solid tumors and hematological malignancies. The ongoing development of BsAb formats will help overcome current clinical issues, such as tumor selectivity and antigen coverage. This report also covers several presentations about emerging targets (e.g. mesothelin, CD47) and new technologies in the field of antibody engineering and therapeutics.
doi_str_mv 10.1093/abt/tbz010
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6913531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/abt/tbz010</oup_id><sourcerecordid>2327937302</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3230-f617f5311fc4db78bae82d1428c067a9be4c43673c393858c18abd503cd5e4283</originalsourceid><addsrcrecordid>eNp9kV1LHDEUhoNUVKw3_gDJjWBLp-ZjPjJeCFa2WhAUVq9DkjmzG5lJ1iQjWPrjm2Wt6E0vDufr4T0HXoQOKflOSctPlU6nSf8mlGyhPVbRuigZrz-9q3fRQYyPhBBGStHWYgftcirKUnCxh_5c28VyyJEi9j1mhLb4LvgE1uGZW1gHEKxb4Pk0jjbhk7vZ1fwLzssfPibvvuGH-cUZVt2zcmbNKZes9t1LoVWEDps8hoDTEoJaWYg4-XWDzWCdNZ_Rdq-GCAeveR89_JzdX14XN7dXvy4vbgrDGSdFX9OmrzilvSk73QitQLCOlkwYUjeq1VCaktcNN7zlohKGCqW7inDTVZApvo_ON7qrSY_QGXApqEGugh1VeJFeWflx4-xSLvyzrFvK8-EscPIqEPzTBDHJ0UYDw6Ac-ClKxlnT8oYTltGvG9QEH2OA_u0MJXLtmMyOyY1jGT56_9gb-s-fDBxvAD-t_if0FzbSnto</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2327937302</pqid></control><display><type>article</type><title>Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic</title><source>DOAJ Directory of Open Access Journals</source><source>Access via Oxford University Press (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Li, Hong ; Li, You ; Wang, Cheng ; Wang, Shouye ; Ho, Mitchell</creator><creatorcontrib>Li, Hong ; Li, You ; Wang, Cheng ; Wang, Shouye ; Ho, Mitchell</creatorcontrib><description>Abstract The 15th Annual Protein Engineering Summit (PEGS) organized by Cambridge Healthtech Institute was held in Boston, USA, from 8 to 12 April 2019. This report highlights the presentations in the Oncology Stream of this meeting with a focus on bispecific antibodies (BsAbs). A variety of BsAb formats with different target antigens (CD3, CTLA4, PD-1, PD-L1, EGFR, HER2, BCMA, CD19, CD20, CD38, CD123, TGFβ, PSMA, etc.) have been discussed, in which the T-cell engaging (anti-CD3) BsAb is the most studied construct to exhibit promising immunotherapeutic activities. The BsAb formats include IgG-like structures or antibody fragments composed of antigen-binding sites only. Preclinical and clinical data from different BsAbs demonstrated the potential therapeutic applications in various solid tumors and hematological malignancies. The ongoing development of BsAb formats will help overcome current clinical issues, such as tumor selectivity and antigen coverage. This report also covers several presentations about emerging targets (e.g. mesothelin, CD47) and new technologies in the field of antibody engineering and therapeutics.</description><identifier>ISSN: 2516-4236</identifier><identifier>EISSN: 2516-4236</identifier><identifier>DOI: 10.1093/abt/tbz010</identifier><identifier>PMID: 31844838</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Meeting Reports</subject><ispartof>Antibody therapeutics, 2019-10, Vol.2 (4), p.79-87</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of Antibody Therapeutics. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3230-f617f5311fc4db78bae82d1428c067a9be4c43673c393858c18abd503cd5e4283</citedby><cites>FETCH-LOGICAL-c3230-f617f5311fc4db78bae82d1428c067a9be4c43673c393858c18abd503cd5e4283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913531/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913531/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,1605,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31844838$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Hong</creatorcontrib><creatorcontrib>Li, You</creatorcontrib><creatorcontrib>Wang, Cheng</creatorcontrib><creatorcontrib>Wang, Shouye</creatorcontrib><creatorcontrib>Ho, Mitchell</creatorcontrib><title>Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic</title><title>Antibody therapeutics</title><addtitle>Antib Ther</addtitle><description>Abstract The 15th Annual Protein Engineering Summit (PEGS) organized by Cambridge Healthtech Institute was held in Boston, USA, from 8 to 12 April 2019. This report highlights the presentations in the Oncology Stream of this meeting with a focus on bispecific antibodies (BsAbs). A variety of BsAb formats with different target antigens (CD3, CTLA4, PD-1, PD-L1, EGFR, HER2, BCMA, CD19, CD20, CD38, CD123, TGFβ, PSMA, etc.) have been discussed, in which the T-cell engaging (anti-CD3) BsAb is the most studied construct to exhibit promising immunotherapeutic activities. The BsAb formats include IgG-like structures or antibody fragments composed of antigen-binding sites only. Preclinical and clinical data from different BsAbs demonstrated the potential therapeutic applications in various solid tumors and hematological malignancies. The ongoing development of BsAb formats will help overcome current clinical issues, such as tumor selectivity and antigen coverage. This report also covers several presentations about emerging targets (e.g. mesothelin, CD47) and new technologies in the field of antibody engineering and therapeutics.</description><subject>Meeting Reports</subject><issn>2516-4236</issn><issn>2516-4236</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9kV1LHDEUhoNUVKw3_gDJjWBLp-ZjPjJeCFa2WhAUVq9DkjmzG5lJ1iQjWPrjm2Wt6E0vDufr4T0HXoQOKflOSctPlU6nSf8mlGyhPVbRuigZrz-9q3fRQYyPhBBGStHWYgftcirKUnCxh_5c28VyyJEi9j1mhLb4LvgE1uGZW1gHEKxb4Pk0jjbhk7vZ1fwLzssfPibvvuGH-cUZVt2zcmbNKZes9t1LoVWEDps8hoDTEoJaWYg4-XWDzWCdNZ_Rdq-GCAeveR89_JzdX14XN7dXvy4vbgrDGSdFX9OmrzilvSk73QitQLCOlkwYUjeq1VCaktcNN7zlohKGCqW7inDTVZApvo_ON7qrSY_QGXApqEGugh1VeJFeWflx4-xSLvyzrFvK8-EscPIqEPzTBDHJ0UYDw6Ac-ClKxlnT8oYTltGvG9QEH2OA_u0MJXLtmMyOyY1jGT56_9gb-s-fDBxvAD-t_if0FzbSnto</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Li, Hong</creator><creator>Li, You</creator><creator>Wang, Cheng</creator><creator>Wang, Shouye</creator><creator>Ho, Mitchell</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201910</creationdate><title>Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic</title><author>Li, Hong ; Li, You ; Wang, Cheng ; Wang, Shouye ; Ho, Mitchell</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3230-f617f5311fc4db78bae82d1428c067a9be4c43673c393858c18abd503cd5e4283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Meeting Reports</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Hong</creatorcontrib><creatorcontrib>Li, You</creatorcontrib><creatorcontrib>Wang, Cheng</creatorcontrib><creatorcontrib>Wang, Shouye</creatorcontrib><creatorcontrib>Ho, Mitchell</creatorcontrib><collection>Access via Oxford University Press (Open Access Collection)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antibody therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Hong</au><au>Li, You</au><au>Wang, Cheng</au><au>Wang, Shouye</au><au>Ho, Mitchell</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic</atitle><jtitle>Antibody therapeutics</jtitle><addtitle>Antib Ther</addtitle><date>2019-10</date><risdate>2019</risdate><volume>2</volume><issue>4</issue><spage>79</spage><epage>87</epage><pages>79-87</pages><issn>2516-4236</issn><eissn>2516-4236</eissn><abstract>Abstract The 15th Annual Protein Engineering Summit (PEGS) organized by Cambridge Healthtech Institute was held in Boston, USA, from 8 to 12 April 2019. This report highlights the presentations in the Oncology Stream of this meeting with a focus on bispecific antibodies (BsAbs). A variety of BsAb formats with different target antigens (CD3, CTLA4, PD-1, PD-L1, EGFR, HER2, BCMA, CD19, CD20, CD38, CD123, TGFβ, PSMA, etc.) have been discussed, in which the T-cell engaging (anti-CD3) BsAb is the most studied construct to exhibit promising immunotherapeutic activities. The BsAb formats include IgG-like structures or antibody fragments composed of antigen-binding sites only. Preclinical and clinical data from different BsAbs demonstrated the potential therapeutic applications in various solid tumors and hematological malignancies. The ongoing development of BsAb formats will help overcome current clinical issues, such as tumor selectivity and antigen coverage. This report also covers several presentations about emerging targets (e.g. mesothelin, CD47) and new technologies in the field of antibody engineering and therapeutics.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>31844838</pmid><doi>10.1093/abt/tbz010</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2516-4236
ispartof Antibody therapeutics, 2019-10, Vol.2 (4), p.79-87
issn 2516-4236
2516-4236
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6913531
source DOAJ Directory of Open Access Journals; Access via Oxford University Press (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Meeting Reports
title Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T22%3A29%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Highlights%20of%202019%20Protein%20Engineering%20Summit%20(PEGS)%20in%20Boston,%20USA:%20advancing%20antibody-based%20cancer%20therapies%20to%20the%20clinic&rft.jtitle=Antibody%20therapeutics&rft.au=Li,%20Hong&rft.date=2019-10&rft.volume=2&rft.issue=4&rft.spage=79&rft.epage=87&rft.pages=79-87&rft.issn=2516-4236&rft.eissn=2516-4236&rft_id=info:doi/10.1093/abt/tbz010&rft_dat=%3Cproquest_pubme%3E2327937302%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2327937302&rft_id=info:pmid/31844838&rft_oup_id=10.1093/abt/tbz010&rfr_iscdi=true